Compare GDRX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDRX | ORGO |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | United States | United States |
| Employees | 738 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.9M | 732.3M |
| IPO Year | 2020 | N/A |
| Metric | GDRX | ORGO |
|---|---|---|
| Price | $2.52 | $3.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | $4.78 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.1M | 885.3K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $800,651,000.00 | $465,218,000.00 |
| Revenue This Year | $2.30 | $8.14 |
| Revenue Next Year | $2.63 | $6.33 |
| P/E Ratio | $29.60 | ★ N/A |
| Revenue Growth | 1.30 | ★ 2.24 |
| 52 Week Low | $2.47 | $2.61 |
| 52 Week High | $5.81 | $7.08 |
| Indicator | GDRX | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 31.70 | 37.78 |
| Support Level | $2.47 | $3.60 |
| Resistance Level | $2.63 | $4.10 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 11.23 | 45.81 |
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.